Detalles de la búsqueda
1.
Exploring Cuneanes as Potential Benzene Isosteres and Energetic Materials: Scope and Mechanistic Investigations into Regioselective Rearrangements from Cubanes.
J Am Chem Soc
; 145(30): 16355-16364, 2023 Aug 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37486221
2.
Aza-Quasi-Favorskii Reaction: Construction of Highly Substituted Aziridines through a Concerted Multibond Rearrangement Process.
J Am Chem Soc
; 144(24): 10943-10949, 2022 06 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35674783
3.
Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists.
Bioorg Med Chem Lett
; 25(6): 1196-205, 2015 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25686852
4.
7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.
Bioorg Med Chem Lett
; 21(22): 6646-51, 2011 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21996520
5.
Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11ß-hydroxydehydrogenase 1 (11ß-HSD1).
Bioorg Med Chem Lett
; 21(22): 6693-8, 2011 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21983444
6.
Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists.
Bioorg Med Chem Lett
; 19(5): 1451-6, 2009 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19201606
7.
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
J Med Chem
; 51(5): 1145-9, 2008 Mar 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-18260618
8.
Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.
Bioorg Med Chem Lett
; 18(17): 4770-3, 2008 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18707880
9.
Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.
Bioorg Med Chem Lett
; 18(6): 1939-44, 2008 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18291645
10.
Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11ß-Hydroxysteroid Dehydrogenase Type 1 (11ß-HSD-1).
ACS Med Chem Lett
; 9(12): 1170-1174, 2018 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-30613321
11.
Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11ß-Hydroxysteroid Dehydrogenase Type 1 Inhibitor.
J Med Chem
; 60(12): 4932-4948, 2017 06 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-28537398
12.
Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11ß-Hydroxysteroid Dehydrogenase Type 1 (11ß-HSD-1).
ACS Med Chem Lett
; 5(7): 803-8, 2014 Jul 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-25050169
13.
Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).
J Med Chem
; 56(18): 7343-57, 2013 Sep 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-23964740
Resultados
1 -
13
de 13
1
Próxima >
>>